Clinical Trials for Uterine Cancer

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic HER2-expressing solid tumors—particularly colorectal and gastroesophageal cancers after progression on standard therapy—and evaluates intravenous trastuzumab deruxtecan (a HER2-targeted antibody-drug conjugate) in combination with oral ceralasertib (a selective ATR kinase inhibitor targeting DNA damage response pathways).

ClinicalTrials.gov ID: NCT04704661

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls children, adolescents, and young adults with recurrent or refractory solid tumors (including lymphomas and desmoid tumors), treating them with intravenous tegavivint, a small molecule inhibitor targeting TBL1 to disrupt Wnt/beta-catenin signaling. Expansion cohorts focus on specific tumor types and Wnt pathway–driven malignancies.

ClinicalTrials.gov ID: NCT04851119

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors, including biomarker-selected cohorts (e.g., ATM loss/alterations; platinum‑resistant high‑grade serous ovarian cancer; selected endometrial, colorectal, and pancreatic cancers), after appropriate standard therapies. Investigational therapy is ART0380, an oral ATR kinase inhibitor exploiting replication-stress/synthetic lethality, given as monotherapy or combined with gemcitabine or irinotecan; includes a randomized cohort of platinum‑resistant ovarian cancer comparing ART0380+gemcitabine versus gemcitabine.

ClinicalTrials.gov ID: NCT04657068

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or persistent epithelial cervical cancer after ≥1 prior systemic chemotherapy (up to two for recurrence allowed), ECOG 0–1, and available archival tissue for TROP-2 testing receive sacituzumab govitecan 10 mg/kg IV D1,8 q21d until progression/toxicity. Sacituzumab govitecan is a Trop-2–targeted antibody–drug conjugate delivering SN-38 (topoisomerase I inhibitor); prior immunotherapy allowed, but exclude prior topo I inhibitors, active CNS mets, bulky >7 cm (unless PI-approved), significant comorbidities, and viral infections with detectable load.

ClinicalTrials.gov ID: NCT05838521

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with MUC16-positive advanced ovarian, primary peritoneal/fallopian tube, or endometrial cancer after prior platinum (and prior anti–PD‑1 for endometrial) receive the investigational MUC16×CD28 costimulatory bispecific REGN5668 alone or combined with anti–PD‑1 cemiplimab, cemiplimab+anti–LAG‑3 fianlimab, or the MUC16×CD3 T‑cell engager ubamatamab (some cohorts with IL‑6R blocker sarilumab for CRS mitigation). Aims to enhance T‑cell activation against MUC16 tumors via CD28 costimulation with or without PD‑1/LAG‑3 blockade or CD3 engagement; key exclusions include prior MUC16‑targeted therapy, active autoimmune/CNS disease, and significant cardiac disease.

ClinicalTrials.gov ID: NCT04590326

Phase II Trial of Hypofractionated Radiochemotherapy for Women With Metastatic or Bulky Uterine Cervix Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women with untreated FIGO 2018 stage IB3–IIIC1 bulky (≥6 cm) or limited-metastatic stage IVB cervical squamous/adenosquamous/adenocarcinoma (GOG PS 0–2) receive a condensed course of pelvic hypofractionated IMRT with two weekly doses of concurrent cisplatin radiosensitization (40 mg/m2) followed by HDR brachytherapy. The study assesses early MRI response, feasibility of timely completion, safety, and preliminary PFS/OS, with exploratory circulating tumor cell dynamics.

ClinicalTrials.gov ID: NCT06331468

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-selected adults with recurrent ovarian (including fallopian tube/primary peritoneal) or endometrial cancer receive abemaciclib, a CDK4/6 inhibitor targeting cyclin D–CDK4/6–RB signaling; ovarian cases require CDK4/6 pathway activation, and endometrioid endometrial tumors must be HR-positive without CCNE amplification or RB loss. Hormone receptor–positive tumors may also receive an aromatase inhibitor (anastrozole or letrozole).

ClinicalTrials.gov ID: NCT04469764

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adult women with recurrent gynecologic carcinosarcoma after at least one prior systemic regimen (ECOG 0–2), this single-arm study gives cabozantinib (oral MET/VEGFR2/AXL multikinase inhibitor) plus dostarlimab (anti–PD-1) with maintenance dosing. Key exclusions include prior cabozantinib, unstable CNS disease, significant bleeding/GI risk, uncontrolled CV/HTN, active autoimmune disease requiring systemic therapy, and contraindicated anticoagulation.

ClinicalTrials.gov ID: NCT05559879

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma (ECOG 0–1) with measurable disease and ≤1 prior systemic chemotherapy in the metastatic/advanced setting receive nab-sirolimus IV (albumin-bound mTORC1 inhibitor) on Days 1 and 8 of 21-day cycles plus daily letrozole. Excludes prior mTOR inhibitor exposure and active brain metastases; aims to assess response by RECIST with treatment continued until progression or intolerance.

ClinicalTrials.gov ID: NCT05997017